ClinicalTrials.gg
RecruitingNCT04930978COVID-19-TBUpdated Nov 22, 2023

Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis

An observational study in COVID-19 Respiratory Infection and Pulmonary Tuberculoses, sponsored by Tuberculosis Research Centre, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Tuberculosis Research Centre, India · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Tuberculosis, Pulmonary with a site in India — 6 open to participants now, 6 under way, 2 of them phase 3. Tuberculosis, Pulmonary · India.

Started
2021
with 2 others
Observational
9 of 27
1 open now
Registered
18th of 27
by date
Lead sponsor
5 of 27
Tuberculosis Research Centre, India

Among the 27 studies in Tuberculosis, Pulmonary with a site in India, this one is one of 3 that started in 2021, is one of 9 observational ones, and was the 18th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

6 of the 27 studies in Tuberculosis, Pulmonary with a site in India are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Tuberculosis, Pulmonary with a site in India, or all of them as a file.
02

Study summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the Coronavirus disease (COVID-19). Tuberculosis (TB) is the foremost cause of infectious deaths globally. In 2025, an additional 1.4 million TB deaths could occur as direct consequence of the COVID-19 pandemic. It is postulated that individuals with latent or active TB are more susceptible to SARS-CoV-2 disease and that COVID-19 disease rate is high in patients with active TB, although the evidence is still scarce. TB and SARS-CoV-2 are both infectious diseases which primarily attack the alveolar region of the lungs and share common symptoms. SARS-CoV-2 disease can induce innate and adaptive immunity, but uncontrolled inflammatory innate immunity and impaired adaptive immune responses may be associated with severe tissue damage, both locally and systemically. People with coinfection (COVID-19 and TB disease) might potentially have impaired protective immune responses and treatment outcomes, specifically as far as anti-tuberculosis treatment is concerned. However, very little is known about the immunological underpinnings in this interface between TB and COVID-19 on the effect of SARS-CoV-2 disease on disease severity, response to treatment and treatment outcomes in pulmonary tuberculosis. Investigators hypothesize that altered immunity due to prior or present asymptomatic disease with SARS-CoV-2 virus can lead to altered immune responses and systems biology, increased severity and altered treatment outcomes in TB disease.

The main objective of the study would be to evaluate the baseline differences in immune cells populations immune cell responses at baseline and at the time of treatment (2nd month) and end of treatment. Further, Investigators would be evaluating the changes in proteomic profiles in a subset of these individuals. In addition, immunological assays examining differences in T cell populations, measuring levels of various cytokines and by immunophenotyping as well as other immune parameters related to innate and adaptive responses will be performed to enhance the understanding of the immunological cross-talk between active TB patients with or without SARS-CoV-2. The secondary objective would be to study the clinical features, disease severity, mycobacterial burden and treatment outcomes in a cohort of SARS-CoV-2 infected (asymptomatic PCR or Antibody+) and non-infected patients with active pulmonary TB.

Read the detailed description

Coronavirus disease (COVID-19) is a new respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family coronaviridae with wide spreading in humans and animals. This virus is enveloped and contains positive-sense, single-stranded RNA with approximately 31 kb of genome size and so far, is considered as the largest known RNA viruses. The COVID-19 infected individuals exhibit low to modest symptoms (cough, fever, and respiratory distress) and transmitted mainly by respiratory droplets. However, around 15% of infected individuals proceed to severe pneumonia and approximately 5% of them progress to acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure. Transmission of SARS-CoV-2 occurs through the means of coughing and sneezing, touching the mouth, nose, eyes, close personal contact and touching a virus-contaminated object. SARS-CoV-2 disease can induce both the arms of innate and adaptive immunity, but uncontrolled inflammatory innate immunity and weakened adaptive immune responses might be associated with destructive tissue damage, both locally and systemically. Patients with severe COVID-19 exhibited decrease of lymphocytes, and the elevation of IL-6, IL-10 and C-reactive protein. The SARS-CoV-2 is a global pandemic threat. Currently, as on August 5, the total number of COVID-19 cases is approximately 18,354,342 with 696147 deaths were reported worldwide and 216 countries are affected. In India, approximately 1,908,254 individuals were infected and 39795 deaths occurred due to COVID-19. SARS-CoV-2 disease is often associated with unconstrained immune response, caused by the hyperactivation of monocytes, macrophages and elevated neutrophils. Both, humoral (production of IgG, IgM, neutralising antibodies and reduced memory B cells) and cell mediated (CD4+, CD8+ and cytotoxic markers) immunity is required for defense against COVID-19. In addition, the activation of Th1 / Th17 cells might induce the exacerbation of the inflammatory response.

Tuberculosis (TB) is one of the most important infectious diseases around the world. Tuberculosis (TB), although largely a curable disease, still remains a major cause of morbidity and mortality worldwide. According to the Global Tuberculosis Report 2019, there are an estimated 10 million incident cases of tuberculosis and killed 1.2 million in 2018 globally. India accounts for 27% of all estimated incident cases worldwide. M. tuberculosis (M.tb) infection could result in the activation of innate (monocytes, macrophages, dendritic cells, neutrophils, mast cells) and adaptive (CD4+ and CD8+ T cells, cytotoxic markers) immune response which are necessary for protection. Protective immunity against M. tuberculosis is not completely understood but depends on a wide range of innate and adaptive immune mechanisms. T cell-mediated immune responses are important in the host control of M. tuberculosis infection. The ability of CD4+ T cells to produce gamma interferon, which activates phagocytes to contain the intracellular pathogen, is central in protection. Indeed, T helper 1 (Th1) cells and the gamma IFN that they produce are crucial for protection against disease. This is evident from the increased risk of tuberculosis in individuals with deficiencies in their IFNγ and interleukin 12 (IL 12; which promotes Th1 cell differentiation) signalling pathways. Many other CD4+ T cell subsets, in addition to gamma IFN producing Th1 cells, may also have a role; for example, IL 17-producing CD4+ T cells were shown to mediate the recruitment of protective Th1 cells to the lung upon M. tuberculosis challenge. Furthermore, increased frequencies of regulatory CD4+ T regulatory (Treg) cells during active disease may ensure that the Th1 cell response is not excessive, and this would help minimize lung damage in tuberculosis. The CD8+ T cell response to M. tuberculosis is normally of a lower magnitude than the CD4+ T cell response; however, CD8+ T cells may modulate phago¬cyte activity or produce molecules such as granulysin that may be directly cytotoxic to the mycobacteria. Similarly, other cytokines, in addition to gamma IFN, may also be crucial; for example, Tumour necrosis factor-alpha is important for establishing the granuloma, which is a well-organized collection of innate and adaptive cells that forms to contain the pathogen. Development of TB disease results from interactions among the environment, the host, and the pathogen, and known risk factors include HIV coinfection, immunodeficiency, diabetes mellitus, overcrowding, malnutrition, and general poverty.

The link between TB and COVID-19 is likely to be bi-directional. The temporary immunosuppression induced by tuberculosis may increase the susceptibility of patients to COVID-19, and COVID may, in turn, also increase susceptibility to TB. In 2025, an additional 1.4 million TB deaths could be occurred as direct consequence of the COVID-19 pandemic. The COVID-19 disease rate was high in patients with active TB. TB and SARS-CoV-2 are both infectious diseases which primarily attack the alveolar region of the lungs and share common symptom patterns. Both CD4 and CD8 counts were severely reduced, and the surviving T cells appeared to demonstrate "functional exhaustion". This T cell depletion and dysfunction may exacerbate active TB. Published studies have reported that patients with TB and other viral infections impede the host immune responses like induction of type I interferons by influenza infection, lower mean of CD4+ and CD8+ T cells and increased viral elimination in sputum, stool and suppression of cellular immunity. Recent studies have reported that cytokines seem to play an important role in COVID-19 and TB, and their plasma levels associated with disease severity. It is predicted that people with coinfection have impaired protective immune responses and treatment outcomes, specifically in terms of anti-tuberculosis treatment. Studies showed that SARS-CoV2 coexistent with TB resulted in a decreased absolute number of CD4+ and CD8+ T cells and reduced antibody levels following SARS-CoV-2 recovery. SARS-CoV-2 with TB patients exhibited prolonged viral elimination from stools and sputum in comparison without TB. Studies have demonstrated that SARS-CoV-2 disease stimulates increased cytokine secretion, like interleukin-1 , gamma interferon, tumour necrosis factor- alpha, interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), that ultimately leads to severe inflammation and their plasma levels were linked with disease severity. However, only limited information is available on the function of antigen-specific T cell-mediated immune response to COVID-19 specifically upon coinfection with tuberculosis, since both the disease primarily affects the lungs.

Limited studies have shown that influenza induces immune system hyperactivity and exacerbates pulmonary tuberculosis, leading to worsening of pulmonary function. Respiratory viral infections coexistent with TB delay the host immune responses and lead to more serious clinical outcomes. Coinfection most probably exacerbates inflammation through heightened secretion of cytokines and accelerates the development of severe acute respiratory syndrome and also worsen the TB disease and its outcome. Hence, Investigators propose that understanding mechanisms of immune regulation during SARS-CoV-2 disease may lead to the development of better therapeutic strategies and the results of our fundamental studies may inform future plans for clinical interventional studies. The main fundamental research component of this study might identify clinical parameters and treatment methods and to understand the immunological mechanism for the severity in coinfected SARS-CoV-2 and TB patients.

Hypothesis: Investigators hypothesize that altered immunity due to present or prior asymptomatic disease with SARS-CoV-2 virus could lead to altered immune responses and systems biology, increased severity and altered treatment outcomes in TB disease.

03

Conditions studied

  • COVID-19 Respiratory Infection
  • Pulmonary Tuberculoses
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diagnosis of SARS-CoV-2 via RT-PCR or antibody testing. Diagnosis of TB and classification of TB treatment outcomes are as per National Tuberculosis Elimination program definitions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age group 18-65;
  • Newly diagnosed smear or GeneXpert positive for TB with or without SARS-CoV-2 (present or prior asymptomatic) disease;
  • Willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Any prior episode of TB disease;
  • Treatment for current TB episode >1 week before enrollment;
  • Drug resistance TB patients;
  • Pregnancy or childbirth within last 6 months;
  • Diabetes, -seropositive and current use of and therapy Mild, Moderate and severe Covid-19 disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • TB patients with SARS-CoV-2 PCR+

    50 TB patients with SARS-CoV-2 PCR+ will be recruited in group 1

  • TB patients with SARS-CoV-2 Ab+

    100 TB patients with SARS-CoV-2 Ab+ will be recruited in group 2

  • TB patients negative for SARS-CoV-2 PCR and Ab

    100 TB patients with SARS-CoV-2 PCR and Ab negative will be recruited in group 3

06

What researchers measure

Primary outcomes

  1. Number of participants with active TB

    Effects of SARS-CoV-2 on TB severity, altered Immunological and systems biological Measured by smear or GeneXpert

    Time frame: Day 1

  2. Number of participants with COVID-19 infection

    Measured by real-time qPCR (quantitative polymerase chain reaction) assay

    Time frame: Day 1

  3. Number of participants with SARS-CoV-2 antibodies

    Measured by SARS-CoV-2 serology

    Time frame: Day 1

  4. Differences in immune responses between the groups

    Measured by immunological assays

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2024, 35 months after the start.

Of 45 observational studies under Tuberculosis, Pulmonary, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2021
First posted
Jun 18, 2021
StartActual
Jun 21, 2021
Primary completionEst.
Jun 20, 2024
CompletionEst.
Jun 20, 2024
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04930978
Lead sponsor
Tuberculosis Research Centre, India
Responsible party
Dr. S. Subash Babu (Scientific Director, Tuberculosis Research Centre, India) — Principal investigator
First posted
Jun 18, 2021
Start date
Jun 21, 2021
Primary completion
Jun 20, 2024 (estimated)
Completion
Jun 20, 2024 (estimated)
Last update
Nov 22, 2023

Study contacts

SUBASH BABU, PhD
Contact
sbabu@icerindia.org
04428369500 ext. 9711
Anuradha Rajamanickam, PhD
Contact
anuradha@icerindia.org
04428369500 ext. 9766
Anuradha Rajamanickam, PhD
principal investigator · National Institute for Research in Tuberculosis-International Centers for Excellence in Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion